Vigil Neuroscience (NASDAQ:VIGL) Shares Up 0.4% - Still a Buy?

Vigil Neuroscience, Inc. (NASDAQ:VIGL - Get Free Report) rose 0.4% on Tuesday . The stock traded as high as $8.03 and last traded at $8.02. Approximately 580,307 shares were traded during mid-day trading, a decline of 15% from the average daily volume of 683,086 shares. The stock had previously closed at $7.99.

Wall Street Analyst Weigh In

VIGL has been the topic of several analyst reports. Citigroup lowered shares of Vigil Neuroscience to a "market perform" rating in a report on Thursday, May 22nd. Citizens Jmp downgraded shares of Vigil Neuroscience from a "strong-buy" rating to a "hold" rating in a research report on Thursday, May 22nd. HC Wainwright downgraded shares of Vigil Neuroscience from a "buy" rating to a "neutral" rating and lowered their price objective for the stock from $14.00 to $8.00 in a research report on Tuesday, May 27th. William Blair downgraded shares of Vigil Neuroscience from a "strong-buy" rating to a "hold" rating in a research report on Thursday, May 22nd. Finally, Wedbush downgraded shares of Vigil Neuroscience from a "strong-buy" rating to a "hold" rating and decreased their target price for the company from $13.00 to $8.00 in a research report on Thursday, May 22nd. Ten research analysts have rated the stock with a hold rating, According to data from MarketBeat, Vigil Neuroscience currently has a consensus rating of "Hold" and an average target price of $10.80.

Vigil Neuroscience Stock Performance

The firm's fifty day moving average is $6.51 and its 200 day moving average is $3.60.

Vigil Neuroscience (NASDAQ:VIGL - Get Free Report) last announced its earnings results on Wednesday, May 7th. The company reported ($0.49) EPS for the quarter, topping the consensus estimate of ($0.53) by $0.04. On average, analysts forecast that Vigil Neuroscience, Inc. will post -2.07 earnings per share for the current fiscal year.

Institutional Trading of Vigil Neuroscience

Several hedge funds and other institutional investors have recently bought and sold shares of VIGL. Blair William & Co. IL acquired a new stake in Vigil Neuroscience in the 4th quarter worth about $551,000. Renaissance Technologies LLC grew its holdings in Vigil Neuroscience by 698.5% during the 4th quarter. Renaissance Technologies LLC now owns 367,300 shares of the company's stock worth $624,000 after acquiring an additional 321,300 shares during the last quarter. Barclays PLC grew its holdings in Vigil Neuroscience by 43.6% during the 4th quarter. Barclays PLC now owns 64,049 shares of the company's stock worth $109,000 after acquiring an additional 19,436 shares during the last quarter. Marshall Wace LLP grew its holdings in Vigil Neuroscience by 85.3% during the 4th quarter. Marshall Wace LLP now owns 266,895 shares of the company's stock worth $454,000 after acquiring an additional 122,853 shares during the last quarter. Finally, Boothbay Fund Management LLC acquired a new position in shares of Vigil Neuroscience in the 4th quarter worth approximately $249,000. Institutional investors and hedge funds own 83.64% of the company's stock.

Vigil Neuroscience Company Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.